News & Updates

Treatment with bimekizumab for 4 years results in satisfactory levels of clinical and health-related quality of life responses, reports a study. The majority of patients with moderate-to-severe plaque psoriasis achieve near-complete skin clearance, while nearly two-thirds have complete skin clearance.

Although guidelines recommend 12 months of dual antiplatelet therapy (DAPT) following a heart attack, results from the DUAL-ACS* trial appear to show otherwise.

In the phase III BaxHTN trial, the highly selective and potent aldosterone synthase inhibitor baxdrostat efficiently controls blood pressure (BP) when added to background antihypertensive therapy for the treatment of uncontrolled or treatment-resistant hypertension (HTN).